NTx-265: Additional Phase IIb data

A subset analysis of patients who received occupational therapy (OT) (about 25%) in the double-blind, international Phase IIb REGENESIS trial in 96 patients showed that NTx-265 significantly reduced NIHSS score from baseline vs. placebo (8.6 vs. 5.1 points). Additionally, NTx-265 significantly improved modified Rankin scores vs. placebo. Stem Cell also said that an analysis of patients who had a single observer throughout the trial (about 69%) showed that all endpoints non-significantly favored the NTx-265 regimen over placebo. In a subgroup of patients with a single observer and who received OT, NTx-265 led to a significant 9.1-point mean reduction from baseline in NIHSS score vs. 3.3 points for placebo. No-dose related treatment mortality was observed. ...